Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-emptive INQOVI in Post-Transplant MDS Patients With MRD
NCT04742634Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- May 2022
- Primary completion
- Nov 2033
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine in myelodysplastic syndrome (MDS), sponsored by Washington University School of Medicine. Started May 2022; status: recruiting.
02
Drugs
decitabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04742634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04742634.